Ricerc@Sapienza

Rimegepant is an oral calcitonin gene-related peptide
(CGRP) receptor antagonist and is currently under
development by Biohaven Pharmaceuticals for the acute
and preventive treatment of migraine. Among patients
with acute migraine, significant clinical efficacy has been
reported with a rimegepant single dose. The completed
pivotal phase II and III trials showed a beneficial action of
rimegepant in terms of pain freedom, pain relief, release
of migraine symptoms and lifestyle recovery. Moreover,

Editorial

Introduction: Migraine is a neurovascular disorder involving neurogenic inflammation and transmission of trigeminovascular nociceptive pathways mediated by Calcitonin Gene-Related Peptide (CGRP). Several small molecules antagonizing the CGRP receptor have been developed as migraine-specific acute medications. The CGRP receptor antagonist ubrogepant, also known as MK-1602, has been recently evaluated in phase III clinical trials for clinical efficacy and long-term safety as an abortive migraine treatment.